The aim is to eventually develop an antibody-based treatment that attacks the leukemic stem cells in AML. We have discovered a certain receptor shows specifically on the cell surface in one of the most common forms of AML. The receptor does not shown on normal blood stem cells and with the help of antibodies we can target treatment to the diseased cells without damaging the healthy blood cells. As part of the continued development of a new drug, our intention now is to protect our discovery by filing a patent application.
Menu